Mu et al. examined 81 newly diagnosed BC patients (T1 to T4) without neoadjuvant therapy and highlighted the significant role of M-MDSCs (CD11b+CD45+CD33+CD14+CD15−) in the BC immune environment. This evidence concerns the gene FUT4 and breast cancer.